Tenon Medical, Inc. — Form 10-Q
Filed November 16, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 72/100
What the filing says
Tenon Medical hired Thomas Batton Jr. as Chief Revenue Officer effective October 1, 2026, with base compensation of $12,500/month plus up to $12,500/month in commissions (25% of first $50K monthly revenue from new physician relationships) and quarterly revenue incentives up to $60K. Concurrently, Nate Grawey was promoted from Chief Commercial Officer to newly-created Chief Strategy and Business Development Officer, with removed day-to-day commercial and field sales responsibilities.
Why this rating
CRO hire with material comp (~$300K annualized base + upside) is significant for $7.3M-market-cap company—represents ~4% of market value in annual salary alone. Organizational restructuring (CCO→strategy role) signals operational shift. Neither clearly positive nor negative without revenue context.
Price action (we called it neutral)
at our read · unknown $0.00 | +10 min · unknown $0.00 ▲ 0.00% | +30 min · unknown $0.00 ▲ 0.00% | +1 hr · unknown $0.00 ▲ 0.00% | +4 hrs · unknown $0.00 ▼ 8.16% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.